Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Heart Failure

Prevention & Chronic Conditions
HFSA 25: Excercise Effects of Aficamten Vs Metoprolol in MAPLE-HCM
Author(s): Gregory Lewis Added: 3 weeks ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance… View more

Heart Failure
ACC 24 Late-Breaker Discussion: The ARISE-HF Trial
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,… View more

Heart Failure

Prevention & Chronic Conditions
Klaus Witte
Klaus Witte is a Cardiologist at the Leeds Institute of Cardiovascular & Metabolic Medicine, Leeds, UK, where his research group focuses on patient-orientated questions with a commitment to enhancing efficacy through the personalised application of new and existing therapies in chronic heart failure (CHF).Challenging conventional teaching around heart rate and exercise capacity in CHF, Dr Witte’s… View more
ESC 25: EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
Author(s): Ahran D Arnold Added: 2 months ago
ESC Congress 2025 - EMORI-HCM finds that right ventricular pacing (iRVP) improves symptoms in obstructive hypertrophic cardiomyopathy (oHCM) patients.Dr Ahran Arnold (Imperial College London, UK) discusses findings from the EMORI-HCM study, exploring electro-mechanically optimised right ventricular pacing as a novel therapeutic approach for patients with oHCM.This interventional trial examined… View more

Electrophysiology & Arrhythmia

Heart Failure
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 8 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Heart Failure

Prevention & Chronic Conditions
AHA 24: The ENDEAVOR Trial
Author(s): Added: 11 months ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the… View more

Heart Failure
Iron Deficiency in LVAD Patients
Author(s): William Herrik Nielsen , Finn Gustafsson Added: 1 year ago

Heart Failure
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 3 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Renal Metabolic

Heart Failure